Is Ozempic a Peptide? Semaglutide, GLP-1 Drugs, and What That Means

Is Ozempic a peptide?

Yes. Ozempic’s active ingredient, semaglutide, is a synthetic peptide. Its label calls it a GLP-1 analogue with 94% sequence homology to human GLP-1, modified at positions 8, 26, and 34. European regulators describe it as an analogue of GLP-1(7-37), a 31-residue chain. Those changes stretch its half-life to roughly 1 week, enabling weekly injection. Ozempic is approved for type 2 diabetes, not weight loss.

What a peptide is, and where FDA draws the line

A peptide is a short chain of amino acids linked by peptide bonds, counted in the tens rather than the hundreds; longer chains are called polypeptides or proteins. GLP-1 is itself a peptide hormone.

FDA draws a narrower line. Its December 2023 draft guidance on peptide drug products defines a peptide as any polymer of 40 or fewer amino acids, and a peptide drug that is not a biological product is approved through a new drug application. At 31 and 39 residues, semaglutide and tirzepatide sit under that ceiling, and both were approved as drugs, not biologics.

How semaglutide was engineered from human GLP-1

Native GLP-1 does not last long: the enzyme dipeptidyl peptidase-4 (DPP-4) clips it within minutes of release. Knudsen and Lau (2019) put native GLP-1’s half-life at 1.5 minutes after intravenous dosing and about 1.5 hours after subcutaneous dosing, and the European Medicines Agency’s Ozempic assessment report puts the intravenous half-life at under 1.5 minutes. Per the Ozempic label’s Description section and the European Medicines Agency’s Ozempic assessment report, three changes turn human GLP-1 into semaglutide:

• Position 8: alanine becomes aminoisobutyric acid (Aib), per the EMA report; the label says the position 8 modification stabilizes semaglutide against degradation by DPP-4.
• Position 26: a C18 fatty di-acid joins this lysine through a hydrophilic spacer, and that tail binds semaglutide to albumin, shielding it from breakdown.
• Position 34: the only other lysine becomes arginine (Arg34), again per the EMA report; the label says this minor modification ensures only one fatty di-acid attaches.

The result keeps 94% sequence homology to human GLP-1 but behaves differently: semaglutide is more than 99% albumin-bound, has an elimination half-life of approximately 1 week, and stays in circulation about 5 weeks after the last dose.

Why you will see both 30 and 31 amino acids

Counts differ because human GLP-1 circulates in two forms: a Molecular Metabolism review on NIH’s PMC (Mueller et al., 2019) reports that about 80% of circulating GLP-1 immunoreactivity is GLP-1(7-36)amide, 30 residues, and about 20% the glycine-extended GLP-1(7-37), 31. Knudsen and Lau call native GLP-1 a 30-amino-acid hormone, meaning the first form. Semaglutide is built on the second: the European Medicines Agency’s Ozempic assessment report describes it as an Aib8, Arg34-GLP-1(7-37) analogue with a side chain attached to the lysine at position 26. The U.S. label describes the modified positions but never states a residue count, so the 31-residue figure comes from the scientific and European regulatory record.

Ozempic vs Wegovy: same peptide, different FDA approvals

Ozempic (type 2 diabetes)

Ozempic injection is indicated, alongside diet and exercise, to improve glycemic control in adults with type 2 diabetes, and to reduce cardiovascular and kidney risk in those with cardiovascular or chronic kidney disease. Dosing starts at 0.25 mg weekly for 4 weeks, then 0.5 mg, to a maximum of 2 mg weekly. As of 2026, “Ozempic” also names a once-daily tablet (1.5, 4, and 9 mg). Neither form is FDA-approved for weight management.

Wegovy (chronic weight management and more)

Wegovy injection is approved, with a reduced-calorie diet and increased physical activity, for long-term weight reduction in adults and patients 12 and older with obesity, and in adults with overweight plus a weight-related condition. It is also approved to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight, and, under accelerated approval, for noncirrhotic MASH with moderate to advanced fibrosis in adults. Dosing escalates every 4 weeks from 0.25 mg to a maintenance dosage of 1.7 mg or 2.4 mg weekly (2.4 mg recommended). For weight reduction in adults who tolerate 2.4 mg for at least 4 weeks, and where additional weight reduction is clinically indicated, the dosage may be increased to a maximum of 7.2 mg weekly. A 25 mg daily tablet is also approved, for cardiovascular risk reduction and weight reduction in adults.

In the Wegovy label’s Study 2, a 68-week trial of 1,961 adults with obesity (or overweight plus a weight-related condition) and without type 2 diabetes, Wegovy 2.4 mg injection plus lifestyle intervention produced a mean body weight change of minus 14.9% (N=1,306), versus minus 2.4% for placebo (N=655). The population matters: in the label’s Study 3, which enrolled 807 adults who did have type 2 diabetes, the mean change was minus 9.6% versus minus 3.4% for placebo. These figures describe the FDA-approved product in specific trial populations, not an expected individual result; compounded products were not studied.

Tirzepatide (Mounjaro and Zepbound): a dual GIP/GLP-1 peptide

Tirzepatide is often lumped in with Ozempic as “a GLP-1 drug,” but it is a different peptide. The European Medicines Agency’s Mounjaro assessment report describes it as “a 39-amino acid synthetic peptide” whose peptide component is based on the GIP (glucose-dependent insulinotropic polypeptide) sequence, with two non-coded aminoisobutyric acid residues and a C20 fatty diacid attached to the lysine at position 20. It activates both the GIP and GLP-1 receptors, which makes it a dual agonist. That tail is the same albumin-binding strategy semaglutide uses, and the report says it gives tirzepatide a mean half-life of approximately 5 days, enabling once-weekly dosing.

Mounjaro and Zepbound

Mounjaro improves glycemic control in adults and patients 10 and older with type 2 diabetes. Zepbound is approved, with diet and exercise, for weight reduction in adults with obesity or overweight plus a weight-related condition, and for moderate to severe obstructive sleep apnea in adults with obesity. Both start at 2.5 mg weekly for 4 weeks, then 5 mg, rising in 2.5 mg steps to the maximums in the table below; on both labels, 2.5 mg is an initiation dose only.

In the Zepbound label’s Study 1, a 72-week trial of 2,539 adults with obesity or overweight plus a weight-related condition and without type 2 diabetes, mean body weight change with lifestyle intervention was minus 15.0% at 5 mg (N=630), minus 19.5% at 10 mg (N=636), and minus 20.9% at 15 mg (N=630), versus minus 3.1% with placebo (N=643). The label’s Study 2, in 938 adults who did have type 2 diabetes, reports smaller mean changes: minus 12.8% at 10 mg and minus 14.7% at 15 mg, versus minus 3.2% with placebo. These are label results for the branded product, not a promise for any individual. See also Zepbound vs Mounjaro.

Ozempic vs Wegovy vs Mounjaro vs Zepbound at a glance

From the brands’ current prescribing information.

Feature	Ozempic	Wegovy	Mounjaro	Zepbound
Active peptide	Semaglutide (31 residues)	Semaglutide (31 residues)	Tirzepatide (39 residues)	Tirzepatide (39 residues)
Receptor targets	GLP-1	GLP-1	GIP and GLP-1	GIP and GLP-1
FDA-approved uses	Type 2 diabetes (injection and tablet); cardiovascular risk; kidney outcomes (injection only)	Weight management; cardiovascular risk in established CV disease; noncirrhotic MASH	Type 2 diabetes	Weight management, sleep apnea with obesity
Route and cadence	Injection weekly; tablet daily	Injection weekly; tablet daily	Injection weekly	Injection weekly
Maintenance or maximum	Up to 2 mg weekly; 9 mg daily (tablet)	1.7 or 2.4 mg weekly; up to 7.2 mg weekly for adult weight reduction; 25 mg daily (tablet, adults)	Up to 15 mg weekly (10 mg, ages 10 and older)	5, 10, or 15 mg weekly

Why peptide drugs are usually injected, and how the pills work

A swallowed peptide is broken down much like the protein in a meal, which is why semaglutide and tirzepatide are injected. Per the Wegovy label, absolute bioavailability of semaglutide is 89% after subcutaneous injection but only about 1% to 2% after the oral tablet. The Rybelsus and Ozempic tablets label reports 0.4% to 1% for Rybelsus.

The tablets work only because they pair semaglutide with an absorption enhancer, salcaprozate sodium (SNAC), and the label’s conditions are strict: empty stomach in the morning, no more than 4 ounces of water, then a 30-minute wait before eating or drinking. The Wegovy label states that semaglutide absorption predominantly occurs in the stomach, and that blood levels vary more with the tablet: in adults with overweight or obesity without type 2 diabetes, 90% on the 25 mg daily tablet averaged 27 to 186 nmol/L, versus 51 to 110 nmol/L on the 2.4 mg weekly injection.

Bioavailability alone does not explain the two schedules. Semaglutide’s elimination half-life is approximately 1 week by either route, which is what allows weekly injection, while the tablet is taken daily, under those strict conditions, at a far larger milligram dose: per the Wegovy label, the 25 mg daily tablet is predicted to reach average concentrations comparable to the 2.4 mg weekly injection.

No compounded semaglutide or tirzepatide is FDA-approved in any form. Where Revive dispenses compounded tirzepatide, it is a subcutaneous injection (see where to inject tirzepatide).

Compounded semaglutide and tirzepatide after the shortages ended

Compounded copies were widely available only while the brands sat on FDA’s shortage list. FDA declared the tirzepatide injection shortage (Mounjaro and Zepbound) resolved on December 19, 2024, and the semaglutide injection shortage (Ozempic and Wegovy) on February 21, 2025. Enforcement discretion for shortage-based compounding then ended in stages, finishing in May 2025.

What is permitted now

Under section 503A, a compounder may not compound, regularly or in inordinate amounts, drugs that are essentially copies of a commercially available product. FDA treats a compounded drug as essentially a copy when it has the same active ingredient as an approved product at the same, similar, or easily substitutable strength, and the approved product can be given by the route prescribed for the compounded drug, unless a prescriber documents a change that produces a significant difference for an identified individual patient. A narrow FDA enforcement policy says the agency does not intend to act on that condition against a compounder that fills four or fewer such prescriptions in a calendar month, and prescriptions documenting a prescriber-determined significant difference are not counted toward those four. The same guidance states that only very rarely should a compounded drug that is essentially a copy be offered to a patient. What ended with the shortages is mass compounding, not every individual prescription.

Either way, compounded semaglutide and tirzepatide are not FDA-approved, and FDA does not review them for safety, effectiveness, or quality. (Section 503A covers state-licensed pharmacies; 503B covers outsourcing facilities.) More in compounded tirzepatide in 2026.

What FDA has reported

As of May 31, 2026, FDA had received 990 adverse event reports tied to compounded semaglutide and more than 730 to compounded tirzepatide. These are reports, not confirmed causation or rates, and state-licensed pharmacies that are not outsourcing facilities need not report to FDA. FDA has also received reports of adverse events, some requiring hospitalization, involving possible dosing errors with compounded injectable semaglutide. Separately, FDA says some semaglutide sold by compounders may be a salt form, such as semaglutide sodium or semaglutide acetate, which are different active ingredients than the approved drugs contain. Verify any prescriber’s and pharmacy’s credentials with your state licensing boards.

Safety basics every GLP-1 peptide shares

All four brands carry the same boxed warning: these drugs caused thyroid C-cell tumors in rodents, and it is unknown whether that risk applies to humans. All four are contraindicated with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and a provider screens the same way before prescribing a compounded preparation meant to contain the same peptide. Compounded semaglutide and tirzepatide are not FDA-approved, and the FDA has not evaluated them for safety, quality, or efficacy or verified their contents and potency.

Gastrointestinal effects are the most commonly reported adverse reactions; the Wegovy label lists nausea, diarrhea, vomiting, constipation, and abdominal pain. The Wegovy and Zepbound labels both advise against combining them with another GLP-1 receptor agonist or a product containing the same active ingredient. See how long semaglutide side effects last and tirzepatide side effects. Research-chemical peptides sold online are not FDA-approved; the FDA July 2026 peptide review explains their status.

How Revive approaches compounded tirzepatide

Revive Longevity is a LegitScript-certified telehealth clinic with licensed providers in all 50 states, and a licensed provider makes every prescription decision after reviewing your health history, medications, and goals. Revive does not offer Ozempic, Wegovy, Mounjaro, or Zepbound, and lists no semaglutide product. Where a provider determines and documents an individual clinical need, Revive may prescribe compounded tirzepatide from a licensed 503A pharmacy at $279 per 4 weeks (pricing is subject to change and depends on provider eligibility).

Compounded tirzepatide is not FDA-approved, and the FDA has not evaluated it for safety, quality, or efficacy; the trial results above belong to the branded products. See the tirzepatide product page or how Revive works. Nothing here is a promise of results.

Frequently asked questions

Is Ozempic a peptide or a hormone?

Both are partly right. Semaglutide, the active ingredient in Ozempic, is a synthetic peptide engineered from human GLP-1, a natural gut hormone. Its FDA label calls it a GLP-1 analogue with 94% sequence homology to human GLP-1, modified at positions 8, 26, and 34; the European Medicines Agency describes the backbone as GLP-1(7-37), a 31-residue chain. It acts on the same receptor as the natural hormone, and it is made by yeast fermentation, not extracted from the body.

Is Ozempic the same as Wegovy?

They contain the same semaglutide molecule but are approved for different uses and doses. Ozempic is approved for type 2 diabetes, with injection doses up to 2 mg weekly. Wegovy is approved for chronic weight management, for reducing major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight, and for noncirrhotic MASH, with a recommended maintenance injection dose of 2.4 mg weekly and, for weight reduction in adults, a maximum of 7.2 mg weekly. Ozempic is not approved for weight loss.

Is tirzepatide (Mounjaro, Zepbound) also a peptide?

Yes. The European Medicines Agency’s Mounjaro assessment report describes tirzepatide as a 39-amino acid synthetic peptide whose peptide component is based on the GIP hormone sequence. It activates both the GIP and GLP-1 receptors, so it is a dual agonist, and it is not semaglutide. Its mean half-life of approximately 5 days enables once-weekly dosing.

Why is Ozempic injected if there is now a pill?

Peptides break down in the digestive tract, so absorption from a tablet is very low. The Wegovy label reports 89% bioavailability after subcutaneous injection versus about 1% to 2% for the tablet, which relies on an absorption enhancer (SNAC) and is absorbed mainly in the stomach. Blood levels also vary more with the tablet, which is taken daily on an empty stomach with a 30-minute wait. Semaglutide’s half-life is about 1 week by either route, which is what allows once-weekly injection.

Can I still get compounded semaglutide or tirzepatide?

Only in limited circumstances. FDA declared the tirzepatide shortage resolved on December 19, 2024 and the semaglutide shortage on February 21, 2025, which ended shortage-based mass compounding. Under section 503A, a compounder may not compound, regularly or in inordinate amounts, drugs that are essentially copies of a commercially available product, so what remains is the individual patient whose prescriber documents a change producing a significant difference from the approved drug. Compounded versions are not FDA-approved and have not been evaluated by FDA for safety, effectiveness, or quality.